AMG 073: Phase II

NPSP partner Amgen Inc. (AMGN, Thousand Oaks, Calif.) presented pooled data from the first 12 weeks of 3 international Phase II trials showing that treatment with AMG 073 reduced serum PTH levels in 215 SHPT patients on hemodialysis. Mean PTH levels were reduced 20-33% in AMG 073 patients compared to a 16% increase in placebo patients, and mean calcium-phosphorous product decreased 28% in AMG 073 patients compared to an increase of 30.6% in placebo patients. AMG 073 was well tolerated with adverse event rates similar in the AMG 073 and placebo groups. ...